Treatment and Prophylaxis for Pertussis
Azithromycin is the preferred first-line antibiotic for both treatment and postexposure prophylaxis of pertussis across all age groups, with specific age-based dosing regimens that are more effective and better tolerated than traditional erythromycin. 1
Treatment Regimens
Azithromycin (Preferred Agent)
- Infants <6 months: 10 mg/kg per day for 5 days
- Infants and children ≥6 months: 10 mg/kg (max 500 mg) on day 1, then 5 mg/kg per day (max 250 mg) on days 2-5
- Adults: 500 mg on day 1, then 250 mg per day on days 2-5 1
Azithromycin offers superior tolerability with fewer gastrointestinal side effects, better adherence due to once-daily dosing, and lacks the significant drug interactions seen with erythromycin and clarithromycin 1.
Alternative Macrolides
Clarithromycin:
- NOT recommended for infants <1 month (unknown IHPS risk)
- Infants and children ≥1 month: 15 mg/kg per day (max 1 g/day) in 2 divided doses for 7 days
- Adults: 1 g per day in 2 divided doses for 7 days 1
Erythromycin:
- NOT preferred for infants <1 month due to infantile hypertrophic pyloric stenosis (IHPS) risk
- Infants ≥1 month and children: 40-50 mg/kg per day (max 2 g/day) in 4 divided doses for 14 days
- Adults: 2 g per day in 4 divided doses for 14 days 1
Non-Macrolide Alternative
Trimethoprim-Sulfamethoxazole (TMP-SMZ): Use only when macrolides are contraindicated, not tolerated, or for macrolide-resistant strains:
- Contraindicated in infants <2 months, pregnant women, and nursing mothers (kernicterus risk)
- Infants ≥2 months and children: TMP 8 mg/kg/day + SMZ 40 mg/kg/day in 2 divided doses for 14 days
- Adults: TMP 320 mg/day + SMZ 1,600 mg/day in 2 divided doses for 14 days 1
Postexposure Prophylaxis
The same antimicrobial agents and dosing regimens used for treatment apply to postexposure prophylaxis. 1
Indications for Prophylaxis
Administer prophylaxis to asymptomatic close contacts when:
- Exposure occurred within 21 days of cough onset in the index patient
- The contact includes infants <12 months (highest priority due to severe disease risk)
- The contact includes women in the third trimester of pregnancy
- There is potential for secondary exposure to high-risk individuals 1
Critical timing: Prophylaxis must be given within 21 days of the index patient's cough onset to prevent symptomatic infection 1.
Important Distinction
Symptomatic household contacts should be treated as active pertussis cases, not given prophylaxis. 1
Special Populations and Safety Considerations
Infants <1 Month (Neonates)
Azithromycin is the ONLY recommended macrolide for this age group due to:
- Erythromycin's association with IHPS (relative risk: infinity in one cohort study with 7/157 exposed infants developing IHPS vs. 0/125 unexposed)
- No reported IHPS cases with azithromycin use
- The mortality risk from untreated pertussis in neonates outweighs potential drug risks 1
Monitor all infants <1 month receiving any macrolide for IHPS and other serious adverse events. 1
Drug Interactions
- Erythromycin and clarithromycin (but NOT azithromycin) inhibit cytochrome P450 CYP3A enzymes
- Avoid concurrent use with: astemizole, cisapride, pimozide, terfenadine
- Exercise caution with: digoxin, triazolam, ergot alkaloids, statins, anticoagulants, many others 1
Pregnancy Categories
- Azithromycin: FDA Category B 1
- Erythromycin: FDA Category B
- Clarithromycin: FDA Category C 1
- TMP-SMZ: FDA Category C, contraindicated in third trimester 1
Clinical Efficacy Considerations
Antibiotics effectively eradicate B. pertussis from the nasopharynx but do NOT alter the subsequent clinical course when started after the catarrhal phase. 2 Early treatment during the catarrhal phase (first 1-2 weeks) can reduce symptom duration and severity, but the primary benefit of treatment is reducing transmission by eliminating bacterial shedding 1.
Approximately 80-90% of untreated patients spontaneously clear B. pertussis within 3-4 weeks, though untreated infants may remain culture-positive for >6 weeks 1.
Common Pitfalls to Avoid
- Do not use erythromycin as first-line in neonates - the IHPS risk is real and documented
- Do not delay prophylaxis beyond 21 days - it becomes ineffective
- Do not give prophylaxis to symptomatic contacts - treat them as cases
- Do not use TMP-SMZ in infants <2 months or pregnant women - kernicterus risk
- Do not expect antibiotics to shorten cough duration if started after the catarrhal phase - manage expectations appropriately